Analystreport

CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC. They now have a $3.50 price target on the stock.

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com